

1 **Convergent epitope-specific T cell responses after SARS-CoV-2 infection and vaccination**

2

3 Anastasia A. Minervina^{1#}, Mikhail V. Pogorelyy^{1#}, Allison M. Kirk¹, E. Kaitlynn Allen¹, Kim J.
4 Allison², Chun-Yang Lin¹, David C. Brice¹, Xun Zhu³, Kasi Vegesana⁴, Gang Wu³, Jeremy Chase
5 Crawford¹, Stacey Schultz-Cherry², Jeremie H. Estep⁵, Maureen A. McGargill¹, the SJTRC Study
6 Team^{*}, Joshua Wolf², Paul G. Thomas¹

7

8 ¹ Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN USA

9 ² Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN USA

10 ³ Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN USA

11 ⁴ Information Services, St. Jude Children's Research Hospital, Memphis, TN USA

12 ⁵ Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN
13 USA

14

15 #Equal contribution

16 ❖ Aditya Gaur, James Hoffman, Motomi Mori, Li Tang, Elaine Tuomanen, Richard Webby, Hana
17 Hakim, Randall T. Hayden, Diego R. Hijano, Resha Bajracharya, Walid Awad, Lee-Ann Van de
18 Velde, Brandi L Clark, Taylor L. Wilson, Robert C. Mettelman, Aisha Souquette, Ashley
19 Castellaw, Ronald H. Dallas, Jason Hodges, Ashleigh Gowen, Jamie Russell-Bell, James Sparks,
20 David E. Wittman, Thomas P. Fabrizio, Sean Cherry, Ericka Kirkpatrick Roubidoux, Valerie
21 Cortez, Pamela Freiden, Nicholas Wohlgemuth, Kendall Whitt;

22

23 Correspondence to Joshua Wolf joshua.wolf@stjude.org and Paul Thomas

24 paul.thomas@stjude.org

25

26 **Abstract**

27

28 SARS-CoV-2 mRNA vaccines, including Pfizer/Biontech BNT162b2, were shown to be effective
29 for COVID-19 prevention, eliciting both robust antibody responses in naive individuals and
30 boosting pre-existing antibody levels in SARS-CoV-2-recovered individuals. However, the
31 magnitude, repertoire, and phenotype of epitope-specific T cell responses to this vaccine, and the

32 effect of vaccination on pre-existing T cell memory in SARS-CoV-2 convalescent patients, are
33 still poorly understood. Thus, in this study we compared epitope-specific T cells elicited after
34 natural SARS-CoV-2 infection, and vaccination of both naive and recovered individuals. We
35 collected peripheral blood mononuclear cells before and after BNT162b2 vaccination and used
36 pools of 18 DNA-barcoded MHC-class I multimers, combined with scRNAseq and scTCRseq, to
37 characterize T cell responses to several immunodominant epitopes, including a spike-derived
38 epitope cross-reactive to common cold coronaviruses. Comparing responses after infection or
39 vaccination, we found that T cells responding to spike-derived epitopes show similar magnitudes
40 of response, memory phenotypes, TCR repertoire diversity, and $\alpha\beta$ TCR sequence motifs,
41 demonstrating the potency of this vaccination platform. Importantly, in COVID-19-recovered
42 individuals receiving the vaccine, pre-existing spike-specific memory cells showed both clonal
43 expansion and a phenotypic shift towards more differentiated CCR7-CD45RA⁺ effector cells. In-
44 depth analysis of T cell receptor repertoires demonstrates that both vaccination and infection elicit
45 largely identical repertoires as measured by dominant TCR motifs and receptor breadth, indicating
46 that BNT162b2 vaccination largely recapitulates T cell generation by infection for all critical
47 parameters. Thus, BNT162b2 vaccination elicits potent spike-specific T cell responses in naive
48 individuals and also triggers the recall T cell response in previously infected individuals, further
49 boosting spike-specific responses but altering their differentiation state. Overall, our study
50 demonstrates the potential of mRNA vaccines to induce, maintain, and shape T cell memory
51 through vaccination and revaccination.

52

53 **Introduction**

54

55 The ongoing COVID-19 pandemic led to the rapid development of novel types of antiviral
56 vaccines, including the mRNA-based Pfizer/Biontech BNT162b2 regimen. Vaccination with
57 BNT162b2 elicits both antibody and T cell responses (Sahin et al. 2020). However, the magnitude
58 of T cell responses in naive individuals following infection or vaccination as well as the effect of
59 vaccination on pre-existing memory cells remains controversial (Camara et al. 2021; Thimme et
60 al. 2021; Painter et al. 2021), in part because the very nature of the T cell response complicates its
61 unbiased quantification. While antibodies bind antigen directly, and thus can be measured and
62 compared among donors using universal assays, T cells recognize antigen presented on the cell

63 surface by the Major Histocompatibility Complex (MHC), which is encoded by the most
64 polymorphic genes in the human population (Robinson et al. 2019). Variability of peptide-MHC
65 across and within donors makes measuring epitope-specific T cell responses challenging, and as a
66 result studies often rely on bulk response (e.g., peptide stimulation) assays. Although peptide
67 stimulation assays in principle can provide an estimate of the total CD8 response, they
68 underestimate the frequency of epitope-specific T cells (Sahin et al. 2021). Staining with MHC-
69 multimers loaded with individual peptides is an alternative approach, but it requires pre-selection
70 of immunogenic peptides. Several immunodominant SARS-CoV-2 epitopes presented by common
71 HLA alleles were discovered in the past year, permitting the tracking of epitope-specific T cell
72 response in infected (Francis et al. 2021; Gangaev et al. 2021; Schreibing et al. 2021; Shomuradova
73 et al. 2020; Kared et al. 2021; Saini et al. 2021; Ferretti et al. 2020; Nielsen et al. 2021; Peng,
74 Yanchun et al. 2020; Rha et al. 2021; Sekine et al. 2020; Schulien et al. 2021; Habel et al. 2020;
75 Nguyen et al. 2021) and vaccinated (Thimme et al. 2021; Sahin et al. 2021) individuals using
76 MHC-multimers. Although at the peak of the infection response reports have described more than
77 10% of CD8+ T cells specific to a single SARS-CoV-2 epitope (Saini et al. 2021; Gangaev et al.
78 2021), a month after infection the frequency of most epitope-specific T cell populations is typically
79 less than 1% (Ferretti et al. 2020; Peng, Yanchun et al. 2020; Kared et al. 2021; Rha et al. 2021).
80 The rapid expansion and subsequent contraction of the T cell response occur in both infection
81 (Thevarajan et al. 2020) and vaccination (Thimme et al. 2021), and careful choice of sampling
82 timepoints is important to compare the magnitude of T cell responses in different donors. The
83 diversity of T cell phenotypes adds another layer of complexity as effector and memory
84 subpopulations differ in longevity, cytotoxic potential, and cytokine production.

85
86 Most vaccines are currently given in early childhood and are assessed by serological measures.
87 When vaccine-induced T cell responses have been measured in humans or model systems, they
88 frequently have reduced magnitude or narrower repertoires compared to natural infection (Cukalac
89 et al. 2009; 2014; Oberle et al. 2016; Cornberg et al. 2006; Malherbe et al. 2008). Therefore, to
90 directly compare the T cell response following infection or mRNA vaccination in naive and
91 recovered COVID-19 individuals, we combined DNA-barcoded MHC-multimer staining (specific
92 for spike and non-spike protein-derived epitopes) with scRNAseq and scTCRseq to profile
93 epitope-specific T cell responses. We identified epitope-specific T cell responses of comparable

94 magnitude and phenotype following infection or naive vaccination, with further expansion of
95 spike-specific T cells after convalescent vaccination. Longitudinal sampling of SARS-CoV-2
96 recovered donors before and after vaccination allowed us to observe clonal expansions and
97 phenotype shifts among spike-specific memory T cells. Although the durability of immune
98 protection provided by natural infection and primary vaccination remains unknown, our data
99 suggest that mRNA vaccination in naive donors induces largely equivalent spike-specific T cell
100 responses as infection, while revaccination with a spike-specific mRNA vaccine in recovered
101 subjects can boost both T cell and antibody responses.

102

103 **Results**

104

105 To investigate the ability of mRNA vaccines to trigger epitope-specific T cell responses as well as
106 the effect of vaccination on memory T cells, we selected a cohort of 19 individuals from SJTRC,
107 an ongoing prospective, longitudinal study of St. Jude Children’s Research Hospital adult (≥ 18
108 years old) employees (Fig. 1A). Nine of these participants had never tested positive for COVID-
109 19 during weekly PCR testing from the time SARS-CoV-2 reached the local area to time of
110 sampling (naive, N1-N9), whereas 10 of the subjects were diagnosed as COVID-19 positive with
111 a PCR test and recovered from mild disease (recovered, R1-R10) during the study period. Both
112 the naive and recovered groups received two doses of the Pfizer-BioNTech BNT162b2 mRNA
113 vaccine. Donors from each group were primarily chosen to ensure they were sampled at similar
114 timepoints after the second dose of vaccine (R: 43 ± 3.5 ; N: 46 ± 3.5 ; Fig. S1A) and exhibited a
115 similar distribution of HLA alleles of interest (Fig. S1B). PBMCs from recovered individuals were
116 additionally obtained prior to the first vaccine dose (“post-infection” group, R1-R6), after the first
117 dose (R7, R8, R10), or immediately subsequent to the second dose of vaccine (R9) (Fig. 1A). In
118 concordance with previous reports (Goel et al. 2021; Krammer et al. 2021; Ebinger et al. 2021),
119 we observed an anti-RBD (Fig. 1B) and anti-spike protein IgG (Fig. S2) boost after vaccination of
120 recovered individuals. Two recovered individuals (R7 and R8) showed decreased RBD IgG post-
121 second dose compared to the post-first dose sampling, though the decreases were minimal.
122 Although it is generally accepted that recovered individuals do not benefit from the second dose
123 of the vaccine (Wang et al. 2021; Mazzoni et al. 2021; Krammer et al. 2021; Goel et al. 2021;
124 Ebinger et al. 2021; Camara et al. 2021), donor R10 clearly exhibited antibody boost due to the

125 second dose of BNT162b2. Overall, anti-RBD (Fig. 1B inset) and anti-spike IgG levels (Fig. S2)
126 were similar between recovered and naive groups after vaccination. As expected, SARS-CoV-2-
127 naive donors were negative for N-protein specific antibodies (Fig. S2), as only the S-protein is
128 included in the vaccine. Thus, in both naive and recovered individuals, BNT162b2 vaccination
129 induces high levels of anti-RBD and anti-spike IgG antibodies.

130
131 To evaluate epitope-specific CD8 T cell responses to mRNA vaccination, we selected 18 SARS
132 CoV-2 epitopes (6 from the S protein and 12 from other proteins) that have been previously
133 described by us or others, are likely to elicit a T cell response, and are presented on the common
134 HLA alleles A*01:01, A*02:01, A*24:02, B*15:01 and B*44:02 (Fig. 1C, Supplementary Table
135 1) (Tarke et al. 2021; Kared et al. 2021; Snyder et al. 2020; Gangaev et al. 2021; Schulien et al.
136 2021; Nelde et al. 2021; Ferretti et al. 2020; Shomuradova et al. 2020; Peng, Yanchun et al. 2020;
137 Sekine et al. 2020). In addition, four of the epitopes (A24_VYI, B15_NQK, B44_AEV and
138 B44_VEN) were highly similar to orthologs from common cold coronaviruses (CCCoV), and the
139 CCCoV variant MHC-dextramers were also included to test the cross-reactive potential of these
140 epitopes.

141
142 PBMCs from each donor were stained with a panel of DNA-barcoded, fluorescently-labeled
143 dextramers (Fig. 1A, Supplementary Table 2) that matched the donors' HLA alleles. For SARS-
144 CoV-2-naive, vaccinated donors, these panels only included spike-derived MHC-dextramers.
145 Epitope-specific T cells (CD3⁺CD8⁺dextramer⁺ cells) were isolated using FACS (Fig. S3) and
146 then subjected to scRNAseq, scTCRseq, and CITEseq using the 10x Chromium platform. We
147 obtained dextramer-positive CD8⁺ T cells from all naive, vaccinated donors and COVID-19
148 infected donors at convalescent timepoints and after vaccination, with varying frequencies. The
149 overall frequency of dextramer-specific cells was quite low ($0.23 \pm 0.05\%$ of CD8⁺ T cells; range:
150 0.02-1% of CD8⁺ T cells), but matched expectations based on epitope-specific memory cells'
151 frequencies observed months after the challenge in other studies (Ferretti et al. 2020; Peng,
152 Yanchun et al. 2020; Kared et al. 2021; Rha et al. 2021). The absolute magnitude of epitope-
153 specific T cell responses was similar across all groups (Fig. 1D) despite varying sources and
154 episodes of antigen exposure.

155

156 Use of the DNA-barcoded dextramers allowed us to deconvolve the overall T cell response to 18
157 distinct epitope-specific responses. For each cell, we calculated the number of unique molecular
158 identifiers (UMIs) per dextramer, and we considered a cell as dextramer-specific if more than 30%
159 of the dextramer-derived UMIs corresponded to that dextramer's specific barcode. This resulted
160 in non-overlapping dextramer-positive and -negative groups of cells for each dextramer (Fig. 2A,
161 Fig. S4). To additionally test this threshold, we considered the dextramer assignment of individual
162 cells among the 15 most abundant T cell clones (i.e., clone sizes ≥ 12 cells) defined by scTCRseq.
163 Eleven of the most abundant clonotypes matched a single specificity across all cells (Fig. 2B),
164 indicating that the dextramer specificity thresholds were generally robust. Interestingly, three of
165 the most abundant TCR clonotypes were assigned to both B15-NQK_Q SARS-CoV-2 and B15-
166 NQK_A CCCoV (HKU1/OC43) orthologs of the spike epitope, supporting our initial hypothesis
167 for potential SARS-CoV-2/CCCoV epitope cross-reactivity. Indeed, the UMI counts for the
168 dextramers with SARS-CoV-2 and CCCoV variants of the epitope correlated strongly (Fig. 2C),
169 suggesting that the exact same cells can bind both versions of the epitope.

170

171 To further demonstrate that a single TCR can recognize both variants of B15-NQK, we made a
172 Jurkat cell line expressing one of the potentially cross-reactive $\alpha\beta$ TCRs. This T cell line
173 successfully recognized both CCCoV and SARS-CoV-2 variants of the peptide, as demonstrated
174 by MHC-multimer staining (Fig. 2D) and peptide stimulation assays (Fig. S5). For 6 of 7 HLA-
175 B*15 positive donors, we also measured antibody IgG levels against the spike protein of common
176 cold betacoronaviruses HKU1 and OC43 prior to infection/vaccination. All of the donors except
177 one had high titers of the antibodies (Fig. S6). Interestingly, the donor lacking antibodies to
178 OC43/HKU1 also had the lowest T cell response to this epitope. These data indicate that SARS-
179 CoV-2 may reactivate cross-reactive memory CD8⁺ T cells established during previous
180 OC43/HKU1 infection.

181

182 Because barcoded dextramers allow us to simultaneously measure the response to multiple
183 epitopes in the same sample on the single-cell level, we also utilized these data to compare the
184 magnitude of the response to different epitopes. These analyses established that the most
185 immunodominant epitopes include A01_TTD, A01_LTD, A02_YLQ and B15_NQK (Fig. 2E).
186 Importantly, these epitopes not only elicited the strongest response, but also were found in all

187 HLA-matched samples. Although we observed responses to all other epitopes, they occurred at
188 lower frequencies and only in a subset of HLA-matched donors. Epitopes A01_TTD, A24_NYN
189 and A01_NTN are affected by mutations in SARS-CoV-2 variants of concern delta (P822L in the
190 ORF1ab protein, L452R in the spike protein) and gamma (P80R in the N protein). However,
191 models predicting peptide-MHC binding (NetMHCpan4.1b; (Reynisson et al. 2020)) suggest that
192 these mutations do not impact the binding of the epitope to the restricting HLA allele, as both
193 variants are predicted to be strong binders (Supplementary Table 3).

194
195 We next asked if we could identify signals corresponding to a T cell boost after the vaccination of
196 SARS-CoV-2 recovered individuals. This can be difficult to resolve, as it requires accounting for
197 clonal expansion of spike-specific T cells after vaccination and contraction of both spike- and non-
198 spike-specific T cells following natural infection. The overall frequency of the spike-specific T
199 cell response remained the same after vaccination, which is unsurprising given that the samples
200 were obtained after memory formation. However, for the A02_YLQ spike epitope, we observed a
201 trend towards a stronger T cell response in the context of vaccination (Fig. 2F). Although the
202 overall frequency of epitope-specific cells may be the same before and after vaccination, or even
203 decreasing after vaccination, the composition can shift due to the expansion of spike-specific
204 clones (Fig. 2G, Fig. S7). Indeed, in 5 out of 6 donors, we observed an increase in the fraction of
205 the spike-specific T cell response in comparison to the non-spike response after vaccination,
206 indicating the recruitment of epitope-specific memory T cells among recovered individuals in the
207 response to vaccination (Fig. 2H).

208
209 To understand if there are any differences in the phenotypes of epitope-specific T cells after natural
210 infection, vaccination of naive, and vaccination of SARS-CoV-2 recovered individuals, we
211 performed single cell gene expression (GEX) analysis. This analysis identified 8 distinct clusters
212 of epitope-specific cells (Fig. 3A). According to the surface expression of conventional memory
213 markers (CCR7 and CD45RA) measured by CITEseq (Fig. 3B) and other markers from scRNAseq
214 (Fig 3C, Supplementary Table 4, Supplementary Table 5), the clusters were annotated as Effector
215 Memory with expression of GZMK (EM-GZMK), EM with reexpression of CD45RA (EMRA),
216 EM with exhaustion markers (EM-Ex), EM with high expression of mitochondrial genes (EM-
217 Mito), Transitional memory (TM), naive/T stem cell-like memory, Cycling, and EM with GATA3.

218 Cells obtained either post-infection or post-vaccination were found across all gene expression
219 clusters (Fig. S8, S9). Thus, natural infection, as well as vaccination, lead to the formation of potent
220 T cell memory, including both highly cytotoxic populations and populations with expression of
221 common markers of durable cellular memory, including TCF7, IL7R, and CCR7 (Fig. 3C).

222
223 To determine if a recall response during vaccination affects the phenotypes of T cells, we compared
224 the GEX cluster distribution of recovered donors post-infection and post-vaccination. Epitope-
225 specific T cells were present in all clusters before and after vaccination, independent of their
226 specificity (Fig. 3D). However, we observed a significant post-vaccination shift towards a more
227 highly differentiated effector phenotype (EMRA) of spike-specific cells, but not for non-spike-
228 specific cells, suggesting that this shift was due to the involvement of spike-specific memory T
229 cells in the recall response to vaccination in convalescent donors (Fig. 3E, ($p=0.007$, one-tailed
230 Wilcoxon rank-sum test).

231
232 Recent publications have linked T cell exhaustion to more severe COVID-19 (Kusnadi et al. 2021;
233 Zheng et al. 2020; Diao et al. 2020). Our epitope-specific data similarly included a cluster with
234 high expression of classical exhaustion markers, including CTLA-4, PD-1, TOX, and TIGIT
235 (Cluster 2, EM-Ex, Fig. 3C). Interestingly, this cluster was present only in a fraction of donors,
236 but was present across all conditions: naive donor after vaccination (donors N3, N6, N9), post-
237 infection (R1, R6), post-first dose in recovered donors (R7), and post-second dose in recovered
238 donors (R4, R9). Thus, the appearance of this cluster was not connected to disease severity or the
239 nature of the antigenic stimulus (vaccine or virus). In concordance with previous reports
240 (Schreibing et al. 2021; Kusnadi et al. 2021), this cluster was composed of highly expanded clones
241 (Fig. S10), with more than 87% of the cluster repertoire occupied by just 10 clones (Fig. 3F). We
242 also observed that a cluster of exhausted cells was in close proximity in UMAP-space with a cluster
243 of cycling cells with high expression of MKI67 and TUBB (Fig. 3A, Fig. 3C), indicating a possible
244 connection between these two phenotypic states. Indeed, the number of cells in an exhausted
245 cluster within a patient strongly correlated with the number of cells in the cluster of cycling cells
246 (Fig. 3G). Thus, the presence of the exhausted cluster is connected to both clonal expansion and
247 cell proliferation, suggesting that donors who have such cells are still in the active rather than
248 memory state of immune response. If the “exhausted” cluster is indeed the feature of an active

249 immune response state, it must be transient. To test this, we looked at the distribution of cells
250 among clusters at two available timepoints for recovered individuals (average time between
251 timepoints was 81 days, range 47-121). Almost all cells from this exhausted cluster were absent
252 from the epitope-specific pool of memory T cells at the later timepoint (Fig. 3H). This was
253 observed for both spike and non-spike-specific cells, indicating that the vaccine does not impact
254 the survival of these “exhausted” cells.

255
256 The majority of the clonotypes in the exhausted cluster are highly expanded and are present among
257 other clusters of memory T cells. While the majority of the “exhausted” T cells apparently die, the
258 clonotype lineage and thus the specificity of T cell response is preserved in the EM and EMRA
259 compartments (Fig. 3I). Importantly, the overall TCR β repertoire diversity (represented by
260 normalised Shannon entropy) is comparable between vaccinated naive donors, post-infection
261 donors, and the post-infection/post-vaccination donors (Fig 3J), suggesting that a diverse repertoire
262 of T cells persists in the memory compartment regardless of antigenic history. This is distinct from
263 other models comparing vaccination to infection (Cukalac et al. 2009; Malherbe et al. 2008).

264
265 We and others have previously shown that T cells recognizing the same epitopes frequently have
266 highly similar T cell receptor sequences (Glanville et al. 2017; Dash et al. 2017). In Fig. 4A, we
267 plot a similarity network of paired unique $\alpha\beta$ TCR sequences from our data (Supplementary table
268 6), using a threshold on the TCRdist (Dash et al. 2017) similarity measure to identify highly similar
269 clonotypes. The clusters of similar sequences almost exclusively consist of TCRs with the same
270 epitope specificity and feature biases in V-segment usage (Fig. S11, S12) and strong preference
271 for certain amino acid residues at certain positions of CDR3 region (Fig. 4B). Importantly, the
272 same motifs in spike-specific TCRs were shared between donors who recovered from natural
273 infection and immunologically naive donors after immunization (Fig. 4C). Furthermore, the most
274 prevalent TCR sequence motif specific to A02_YLQ was present across all HLA-matched samples
275 studied. This suggests that epitope recognition is achieved by the same TCR-pMHC molecular
276 interactions, and thus one could expect similar specificity to potential epitope variants for memory
277 T cells elicited by vaccination or natural infection.

278

279 **Discussion**

280

281 Vaccination was shown to be effective in preventing COVID-19, but durability of protection is yet
282 to be determined. It is critical to understand if pre-existing SARS-CoV-2 immunity could be
283 successfully boosted through vaccination. We show that the Pfizer/Biontech BNT162b2 vaccine
284 boosts both antibody levels and T cells specific for SARS-CoV-2 spike protein in individuals with
285 pre-existing immunity for natural infection. We also show that there is no profound difference in
286 frequency, phenotype, or TCR motifs in memory T cells generated by natural infection and
287 vaccination. Taken together, this suggests that mRNA vaccines would be also effective for
288 boosting of pre-existing vaccine-induced immunity during revaccination. The direct comparison
289 between infection- and vaccine-elicited T cell responses has not been well-studied previously in
290 humans as most vaccines are given in very young children. The success of those vaccines also
291 limits the population that acquire natural infection as a comparator group.

292

293 We also discovered T cells cross-reactive for SARS-CoV-2 and common cold coronavirus variants
294 of an HLA*B15-restricted immunodominant epitope. The possibility of this cross-reactivity was
295 hypothesized in (Minervina et al. 2021), where the clonotypes with this TCR motif were the most
296 expanded in an HLA-B*15 positive donor. Francis et al. recently described HLA-B*07_SPR,
297 another epitope from N-protein, as being cross-reactive with HKU1 and OC43 common-cold
298 coronaviruses. The extent of protection in HLA-B*15 and HLA-B*07 positive donors recently
299 infected with common cold coronaviruses is yet to be determined, but a high frequency of cross-
300 reactive CD8 T cells may be a correlate of protection.

301

302 Using longitudinal sampling, we show that certain T cell populations, including differentiated
303 effector cells with exhaustion markers or actively proliferating T cells, are transient and not found
304 in the same donor at later timepoints. Expanded clones contributing to these transient clusters
305 persist in other clusters with long lived memory phenotype. This result agrees with the functional
306 experiment from Gangaev et al. who showed that a fraction of epitope specific T cells sampled
307 close to acute infection timepoints are dysfunctional, but restore IFN γ /TNF α production
308 further into convalescence. The exhausted T cell phenotype was previously linked to more severe
309 disease (Kusnadi et al. 2021; Zheng et al. 2020; Diao et al. 2020), but our data suggests that time

310 since immune stimulus (either infection or vaccination) could also explain the presence of these
311 exhausted effectors. Given that many severe patients may have extended viral replication
312 dynamics, their sampling may occur closer to recent antigen exposure. This does not preclude the
313 accumulation of exhausted T cells as contributing to severe disease phenotypes, but it also might
314 merely be a correlate of extended antigen exposure. Further, the presence of this exhausted
315 phenotype in subjects with all forms of antigen exposure indicates that the presence of these cells
316 is not sufficient to cause significant pathology.

317
318 An important limitation of our study is that we could not compare the effect of one vs two doses
319 of mRNA vaccine in individuals with pre-existing immunity. It has been suggested in multiple
320 studies that a second vaccine dose in individuals with pre-existing immunity does not further
321 increase antibody levels from the first dose (Wang et al. 2021; Mazzoni et al. 2021; Krammer et
322 al. 2021; Goel et al. 2021; Ebinger et al. 2021; Camara et al. 2021), but the effect on T cells remains
323 to be studied. We found an increase in the fraction of EMRA T cells in fully vaccinated subjects
324 with pre-existing immunity. Whether or not this increase is associated with more (or less) durable
325 and efficient protection is not clear. Longer term follow-up studies of the durability of memory in
326 vaccine-only, infection-only, and vaccinated after infection groups should closely monitor the
327 phenotype of antigen-specific T cell responses.

328
329 Precise measurement of epitope-specific T cell and B cell responses is crucial for defining the
330 correlates of SARS-CoV-2 protection, which will inform vaccination strategies to prevent
331 pandemic recurrence as additional SARS-CoV-2 variants emerge. The striking similarity between
332 the phenotypes and constituent repertoires of epitope-specific CD8 T cell responses following
333 infection, vaccination, or infection followed by vaccination, indicate that mRNA vaccines are
334 capable of inducing equivalent memory as an infection episode and further expanding these
335 responses if previously established. These data further suggest that booster shots, if needed to
336 address antibody-escape, will not substantially alter the repertoires of established anti-spike T cell
337 memory. These data are a stark contrast to annual, non-adjuvanted split influenza vaccines, where
338 repeated vaccination has raised some concerns of immune imprinting, tolerance, and reduced
339 vaccine efficacy (Petrie and Monto 2017). While longer term comparative studies between

340 vaccinated and infected individuals are necessary, our results establish BN162b2 vaccination as a
341 potent inducer of SARS-CoV-2 specific CD8 T cells with a profile equivalent to natural infection.

342

343 **Methods**

344

345 **Human cohort**

346 The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study (SJTRC,
347 NCT04362995) is a prospective, longitudinal cohort study of St. Jude Children's Research
348 Hospital adult (≥ 18 years old) employees. The St. Jude Institutional Review Board approved the
349 study. Participants provided written informed consent prior to enrollment and then completed
350 regular questionnaires about demographics, medical history, treatment, and symptoms if positively
351 diagnosed by PCR with SARS-CoV-2. Study data are collected and managed using REDCap
352 electronic data capture tools hosted at St. Jude (Harris et al. 2009; 2019). Participants were
353 screened for SARS-CoV-2 infection by PCR approximately weekly when on St. Jude campus. For
354 this study, we selected a cohort of 19 individuals, nine of which had never tested positive for
355 COVID-19 (naive, N1-N9), and 10 of which were diagnosed as COVID-19 positive with a PCR
356 test and recovered from mild disease (recovered, R1-R10) during the study period. All individuals
357 in this study received two doses of the Pfizer-BioNTech BNT162b2 mRNA vaccine and, most
358 importantly, were sampled at similar time points after their vaccine regimen was complete
359 (Recovered: 43 ± 3.5 ; Naive: 46 ± 3.5 ; Fig. S1A). These individuals also expressed a similar
360 distribution of HLA allele of interest (A01:01, A02:01, A24:02, B15:01, B44:02; Fig. S1B).
361 Finally, the individuals chosen for each group were of similar ages (Recovered: 44.5 ± 4.9 years;
362 Naive: 42.7 ± 3.5 years). For this study, we utilized the convalescent blood draw for SARS-CoV-
363 2 infected individuals (3-8 weeks post diagnosis) and the post-vaccination samples for both SARS-
364 CoV-2 convalescent and naive individuals (3-8 weeks after completion of the vaccine series).
365 Blood samples were collected in 8 mL CPT tubes and separated within 24 hours of collection into
366 cellular and plasma components and aliquoted and frozen for future analysis. Human cohort
367 metadata can be found in the Supplementary Table 2.

368

369

370

371 **HLA typing**

372 High quality DNA was extracted from whole blood aliquots from each participant using the Zymo
373 Quick-DNA 96 Plus Kit (Qiagen). DNA was quantified on the Nanodrop. HLA typing of each
374 participant was performed using the AllType NGS 11-Loci Amplification Kit (One Lambda; Lot
375 013) according to manufacturer's instructions. Briefly, 50 ng DNA was amplified using the
376 AllType NGS 11-Loci amplification primers, and the amplified product was cleaned and
377 quantified on the Qubit 4.0 (Invitrogen). Library preparation of purified amplicons was carried out
378 as described in the protocol, and the AllType NGS Index Flex Kit (Lot 011) was used for barcoding
379 and secondary amplification. Purified, barcoded libraries were quantified using the Qubit DNA
380 HS kit (Invitrogen) and pooled according to the One Lambda Library Pooling table. Pools of up to
381 48 libraries were then purified and then quantified on the TapeStation D5000 (Agilent) before
382 sequencing on a full MiSeq lane at 150x150bp following manufacturer's sequencing
383 specifications. HLA types were called using the TypeStream Visual Software from One Lambda.
384 HLA typing results can be found in the Supplementary Table 2.

385

386 **Variant of concern mutation analysis**

387 We used the WHO definition of variant of concern and variant of interest updated July 6, 2021. A
388 mutation was included in the analysis if it appears in at least 10% of the GISAID isolates with the
389 same Pango lineage (Rambaut et al. 2020). To analyze the predicted binding of variant and wild
390 type peptides we used NetMHCpan 4.1b (Reynisson et al. 2020). Results of this analysis are in
391 Supplementary Table 3.

392

393 **Dextramer generation and cell staining**

394 Peptides with >95% purity were ordered from Genscript and diluted in DMSO to 1 mM. pMHC
395 monomers (500 nM) were generated with easYmer HLA class I (A*01:01, A*02:01, A*24:02,
396 B*15:01, B*44:02) kits (Immunaware) according to the manufacturer's protocol. To generate
397 DNA-barcoded MHC-dextramers we used Klickmer technology (dCODE Klickmer, Immudex).
398 16.2 µL of HLA monomer (500 nM) were mixed with 2 µL barcoded dCODE-PE-dextramer to
399 achieve an average occupancy of 15 and incubated for at least 1 hour on ice prior to use. Individual
400 dextramer cocktails were prepared immediately before staining (Supplementary Table 2). Each
401 cocktail had 1.5 µL of each HLA-compatible barcoded MHC-dextramer-PE and 0.15 µL 100 µM

402 biotin per dextramer pre-mixed to block free binding sites. Samples were divided into 3 batches,
403 and timepoints from the same donor were always processed simultaneously. Donor PBMCs were
404 thawed and resuspended in 50 μ L FACS buffer (PBS, 0.5% BSA, 2 mM EDTA). Cells were
405 stained with 5 μ L Fc-block (Human TruStain FcX, Biolegend 422302) and a cocktail of dextramers
406 for 15 minutes on ice. After this a cocktail of fluorescently-labeled surface antibodies (2 μ L of
407 each: Ghost Dye Violet 510 Viability Dye, Tonbo Biosciences 13-0870-T100; anti-human CD3
408 FITC-conjugated (Biolegend 300406, clone UCHT1), anti-human CD8 BV711-conjugated
409 (Biolegend, 344734, clone SK1)) and TotalSeq-C antibodies (1 μ L anti-human CCR7 (Biolegend
410 353251), 1 μ L anti-human CD45RA (Biolegend 304163)) and 2 μ L of TotalSeq-C anti-human
411 Hashtag antibodies 1-10 (Biolegend 394661, 394663, 394665, 394667, 394669, 394671, 394673,
412 394675, 394677, 394679) were added. Samples were incubated for 30 minutes on ice. Single, Live,
413 CD3-positive, CD8-positive, dextramer-positive cells were sorted into RPMI (Gibco) containing
414 10% FBS and 1% penicillin/streptomycin. Sorted cells were immediately loaded into a 10x
415 reaction. Chromium Next GEM Single Cell 5' kits version 2 (10x Genomics PN: 1000265,
416 1000286, 1000250, 1000215, 1000252 1000190, 1000080) were used to generate GEX, VDJ and
417 Cite-Seq libraries according to the manufacturer's protocol. Libraries were sequenced on Illumina
418 NovaSeq at 26x90bp read length.

419

420 **Single cell RNAseq data analysis**

421 Raw data was processed with Cell Ranger version 6.0.0 (10X Genomics). Three batches were
422 subsequently combined using the aggregate function with default parameters. Resulting GEX
423 matrices were analysed with the Seurat R package version 3.2.3 (Stuart et al. 2019). Following
424 standard quality control filtering, we discarded low quality cells ($nFeatures < 200$ or over 5000,
425 $MT\% > 10\%$) and eliminated the effects of cell cycle heterogeneity using the CellCycleScoring and
426 ScaleData functions. Next, we identified 2000 variable gene features. Importantly, we discarded
427 TCR/Ig genes from variable features, so that the gene expression clustering would be unaffected
428 by T cell clonotype distributions. Next, we removed all non-CD8 cells from the data as well as
429 cells labeled with antibody hashtag #1 (Biolegend 394661) in batch 3, which were used solely as
430 carrier cells for the 10X reaction. Differentially expressed genes between clusters were found using
431 the Seurat FindAllMarkers function with default parameters, and resolution parameter set to 0.5.
432 Differentially expressed genes for 8 resulting clusters can be found in Supplementary Table 4. R

433 scripts for the final Seurat object generation can be found on GitHub
434 (https://github.com/pogorely/COVID_vax_CD8).

435

436 **Donor and epitope assignment using feature barcodes**

437 Cells were processed in 3 batches (each batch making a separate 10x Chromium reaction). In each
438 batch, each PBMC sample was uniquely labeled with a DNA-barcoded hashing antibody
439 (TotalSeq-C anti-human Hashtag antibodies 1-10, Biolegend). We attributed a cell to a certain
440 donor if more than 50% of UMIs derived from hashing antibodies were from the hashtag
441 corresponding to that donor. Cells specific to certain dextramers were called similarly: we required
442 more than 30% of dextramer-derived UMIs to contain a dextramer-specific barcode, and if
443 multiple dextramers passed this threshold the cell was considered specific to both. If the most
444 abundant dextramer barcode per cell was ≤ 3 UMIs, we did not assign any epitope specificity to
445 it. TCR α and TCR β sequences were assembled from aggregated VDJ-enriched libraries using
446 CellRanger (v. 6.0.0) vdj pipeline. For each cell we assigned the TCR β and TCR α chain with the
447 largest UMI count. The R script performing feature barcode deconvolution, GEX and TCR join is
448 available on Github (https://github.com/pogorely/COVID_vax_CD8) as well as the resulting
449 Supplementary Table 5.

450

451 **TCR repertoire analysis**

452 A T cell clone was defined as a group of cells from the same donor which have the same nucleotide
453 sequences of both CDR3 α and CDR3 β (see Supplementary Table 6 for unique T cell clones). To
454 measure the distance between TCR α/β clonotypes and plot logos for dominant motifs we used the
455 TCRdist algorithm implementation and plotting functions from *conga* python package (Schattgen
456 et al. 2020). TCR β repertoire diversity calculation was performed using normalized Shannon
457 entropy $-\left(\sum_{i=1}^n p_i \log_2(p_i)\right) / \log_2(n)$, where n is a total number of unique TCR β clonotypes, and
458 p_i is a frequency of i -th TCR β clonotype (defined as the fraction of cells with this TCR β of all
459 cells in a sample with defined TCR β). Similarity network analysis and visualization were
460 performed with the *igraph* R package (Csardi and Nepusz 2006) and *gephi* software (Jacomy et
461 al. 2014).

462

463

464 **Artificial antigen-presenting cells (aAPCs)**

465 A gBlock gene fragment encoding full-length HLA-B*15:01 was synthesized by Genscript and
466 cloned into the pLVX-EF1 α -IRES-Puro lentiviral expression vector (Clontech). Lentivirus was
467 generated by transfecting 293T packaging cell line (American Type Culture Collection (ATCC)
468 CRL-3216) with the pLVX lentiviral vector containing the HLA-B*15:01 insert, psPAX2
469 packaging plasmid (Addgene plasmid #12260), and pMD2.G envelope plasmid (Addgene plasmid
470 #12259). Viral supernatant was harvested and filtered 24- and 48-hours post-transfection, then
471 concentrated using Lenti-X Concentrator (Clontech). K562 cells (ATCC CCL-243) were
472 transduced, then antibiotic selected for one week using 2 μ g/mL puromycin in Iscove's Modified
473 Dulbecco's Medium (IMDM; Gibco) containing 10% FBS and 1% penicillin/streptomycin.
474 Surface expression of HLA was confirmed via flow cytometry using antibodies against HLA-A,
475 B, C (PE-conjugated, Biolegend 311406, clone W6/32).

476

477 **TCR-expressing Jurkat 76.7 cells**

478 TCR α (TRAV21, CAVHSSGTYKYIF, TRAJ40) and TCR β (TRBV7-2, CASSLEDTNYGYTF,
479 TRBJ1-2) chains matching both the biggest B15_NQK-specific motif on Fig 4B and prediction
480 from (Minervina et al. 2021) were selected for Jurkat cell line generation. TCR α and TCR β chains
481 for the selected B15_NQK-specific TCR were modified to use murine constant regions (murine
482 TRAC*01 and murine TRBC2*01). A gBlock gene fragment was synthesized by Genscript to
483 encode the modified TCR α chain, the modified TCR β chain, and mCherry, with all three genes
484 linked together by 2A sites. This sequence was cloned into the pLVX-EF1 α -IRES-Puro lentiviral
485 expression vector (Clontech). Lentivirus was generated by transfecting 293T packaging cell line
486 (ATCC CRL-3216) with the pLVX lentiviral vector containing the TCR-mCherry insert, psPAX2
487 packaging plasmid (Addgene plasmid #12260), and pMD2.G envelope plasmid (Addgene plasmid
488 #12259). Viral supernatant was harvested and filtered 24- and 48-hours post-transfection, then
489 concentrated using Lenti-X Concentrator (Clontech). Jurkat 76.7 cells (a gift from Wouter
490 Scheper; variant of TCR-null Jurkat 76.7 cells that expresses human CD8 and an NFAT-GFP
491 reporter) were transduced, then antibiotic selected for 1 week using 1 μ g/mL puromycin in RPMI
492 (Gibco) containing 10% FBS and 1% penicillin/streptomycin. Transduction was confirmed by
493 expression of mCherry, and surface TCR expression was confirmed via flow cytometry using

494 antibodies against mouse TCR β constant region (PE-conjugated, Biolegend 109208, clone H57-
495 597) and human CD3 (Brilliant Violet 785-conjugated, Biolegend 344842, clone SK7).

496

497 **Intracellular cytokine staining functional assay**

498 Jurkat 76.7 cells expressing the B15_NQK-specific TCR (2.5×10^5) were cocultured with HLA-
499 B*15:01 aAPCs (2.5×10^5) pulsed with 1 μ M of either NQKLIANAF peptide from HKU1/OC43
500 common cold coronaviruses or NQKLIANQF peptide from SARS-CoV2, 1 μ g/mL each of anti-
501 human CD28 (BD Biosciences 555725) and CD49d (BD Biosciences 555501), brefeldin A
502 (GolgiPlug, 1 μ L/mL; BD Biosciences 555029), and monensin (GolgiStop, 0.67 μ L/mL; BD
503 Biosciences 554724). An unstimulated (CD28, CD49d, brefeldin A, monensin) and positive
504 control (brefeldin A, monensin, 1X Cell Stimulation Cocktail, PMA/ionomycin; eBioscience 00-
505 4970-93) were included in each assay. Cells were incubated for 6 hours (37 $^{\circ}$ C, 5% CO $_2$).
506 Following the 6-hour incubation, cells were washed twice with FACS buffer (PBS, 2% FBS, 1
507 mM EDTA), then blocked using human Fc-block (BD Biosciences 564220). Cells were then
508 stained with 1 μ L Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-T100) and a
509 cocktail of surface antibodies: 1 μ L each of anti-human CD8 (Brilliant Violet 785-conjugated,
510 Biolegend 344740, clone SK1), anti-human CD3 (Brilliant Violet 421-conjugated, Biolegend
511 344834, clone SK7), and anti-mouse TCR β chain (PE-conjugated (Biolegend 109208) or
512 APC/Fire750-conjugated (Biolegend 109246), clone H57-597). Cells were then washed twice with
513 FACS buffer, then fixed and permeabilized using the Cytfix/Cytoperm Fixation/Permeabilization
514 kit (BD Biosciences) according to the manufacturer's instructions. Following fixation and
515 permeabilization, cells were washed twice with 1X Perm/Wash buffer and stained with a cocktail
516 of intracellular antibodies: 1.25 μ L of anti-human IFN γ (Alexa Fluor 647-conjugated, Biolegend
517 502516, clone 4S.B3) and 1 μ L anti-human CD69 (PerCP-eFluor710-conjugated, eBioscience 46-
518 0699-42, clone FN50). Cells were then washed twice with 1X Perm/Wash buffer and analyzed by
519 flow cytometry on a custom-configured BD Fortessa using FACSDiva software (Becton
520 Dickinson). Flow cytometry data were analyzed using FlowJo software (TreeStar).
521 Responsiveness to peptide stimulation was determined by measuring frequency of NFAT-GFP,
522 IFN γ , and CD69 expression.

523

524

525 **Tetramer generation and Jurkat Cell line staining**

526 Biotinylated HLA-B*15-monomers loaded with NQKLIANQF (SARS-CoV-2) and
527 NQKLIANAF (CCCoV) versions of the peptide were tetramerised using TotalSeq-C-0951-PE-
528 Streptavidin (Biolegend 405261) and TotalSeq-C-0956-APC-Streptavidin (Biolegend 405283). 60
529 μ L of HLA-monomers were mixed with 1 μ L of PE-conjugated (for B15_NQKLIANQF) and
530 APC-conjugated for (B15_NQKLIANAF) streptavidin reagents and incubated for 1 hour in the
531 dark on ice. Jurkat 76.7 cells expressing the potentially cross-reactive TCR were stained with 1 μ L
532 Ghost Dye Violet 510 Viability Dye (Tonbo Biosciences 13-0870-T100) and 5 μ L of each MHC-
533 tetramer. Flow cytometry data were analyzed using FlowJo software (TreeStar). Cross-reactivity
534 of the Jurkat 76.7 T cell line was determined by co-staining of the live cells with PE and APC-
535 labeled MHC-tetramers.

536

537 **Recombinant SARS-CoV-2 proteins and ELISA**

538 Expression plasmids for the nucleocapsid (N) protein, spike protein, and the spike receptor binding
539 domain (RBD) from the Wuhan-Hu-1 isolate were obtained from Florian Krammer. Proteins were
540 transfected into Expi293F cells using a ExpiFectamine 293 transfection kit (Thermo Fisher
541 Scientific) as previously described (Amanat et al. 2020). Supernatants from transfected cells were
542 harvested and purified with a Ni-NTA column.

543 For hCoV and SARS-CoV-2 antibody detection, 384-well microtiter plates were coated overnight
544 at 4 °C, with recombinant proteins diluted in PBS. Optimal concentrations for each protein and
545 isotype were empirically determined to optimize sensitivity and specificity. SARS-CoV-2 spike
546 RBD was coated at 2 μ g/mL in PBS. Full-length spike was coated at 2 μ g/mL for IgG. N protein
547 was coated at 1 μ g/mL. The spike proteins of hCoV-229E (Sino Biological, 40605-V08B), hCoV-
548 NL63 (Sino Biological, 40604-V08B), hCoV-HKU1 (Sino Biological, 40606-V08B), or hCoV-
549 OC43 (Sino Biological, 40607-V08B) were coated at 1 μ g/mL for IgG detection. For all ELISAs,
550 plates were washed the next day three times with 0.1% PBS-T (0.1% Tween-20) and blocked with
551 3% OmniblokTM non-fat milk (AmericanBio; AB10109-01000) in PBS-T for one hour. Plates were
552 then washed, and incubated with plasma samples diluted 1:50 in 1% milk in PBS-T for 90 minutes
553 at room temperature. Prior to dilution, plasma samples were incubated at 56 °C for 15 minutes.
554 ELISA plates were washed and incubated for 30 minutes at room temperature with anti-human
555 secondary antibodies diluted in 1% milk in PBS-T: anti-IgG (1:10,000; Invitrogen, A18805). The

556 plates were washed and incubated at room temperature with OPD (Sigma-Alrich, P8287) for 10
557 minutes (for hCoV ELISAs) or SIGMAFAST OPD (Sigma-Alrich; P9187) for 8 minutes (for
558 SARS-CoV-2 ELISAs) and absorbances were measured at 490 nm on a microplate reader. To
559 ensure the specificity of this assay, we first screened samples from a prior study that included
560 young children to identify samples to serve as negative controls. In addition, as a control for plate-
561 to-plate variability, we selected two positive samples from the SJTRC cohort that were tested on
562 each plate and used to calculate the percent ratio, which is the OD of each sample relative to the
563 OD of the control samples. Samples with a percent ratio greater than three times the average of the
564 negative controls were considered positive for the hCoV and two times the average of the negative
565 controls for the SARS-CoV-2 antigens. Antibody levels for each donor can be found in the
566 Supplementary Table 2.

567

568 **Statistical analysis**

569 Statistical analysis was performed in R version 4.0.3. Wilcoxon signed-rank test was used to
570 compare paired pre-vaccination and post-vaccination samples, Wilcoxon rank-sum test was used
571 to compare unpaired samples between study groups.

572

573 **Data and code availability**

574 Code required to reproduce source data for figures is available on GitHub:
575 https://github.com/pogorely/COVID_vax_CD8. All data produced in the study is available as
576 supplementary files. Raw sequencing data was deposited to Short Read Archive acc.
577 PRJNA744851.

578

579 **Acknowledgements**

580 We thank all the donors who volunteered for the SJTRC study, Phil Bradley and Stefan Schattgen
581 for their consultations on TCRdist and conga algorithms, Greig Lennon from St. Jude Immunology
582 flow core for his help with FACS, and Hartwell Center for high-throughput sequencing. This work
583 was funded by ALSAC at St. Jude, the Center for Influenza Vaccine Research for High-Risk
584 Populations (CIVR-HRP) contract number 75N93019C00052 (S.S-C, P.G.T), the St. Jude Center
585 of Excellence for Influenza Research and Surveillance (S.S-C, M.A.M, P.G.T),

586 HHSN272201400006C, 3U01AI144616-02S1 (P.G.T, M.A.M, S.S-C), and R01AI136514
587 (P.G.T).

588

589 **Author Contributions**

590 Conceptualization: A.A.M, M.V.P, E.K.A, J.C.C. and P.G.T. Formal analysis: A.A.M, M.V.P,
591 A.M.K, J.C.C, M.A.M, J.W, J.H.E, X.Z, K.V, G.W. Investigation: A.A.M., M.V.P, A.M.K,
592 M.A.M, J.W, J.E., C-Y.L, D.B. Methods development: A.A.M, M.V.P, A.M.K, C-Y.L, S.S-C,
593 M.A.M. Resources: S.S-C, M.A.M, P.T, J.H.E., J.W. Data and sample curation: J.W, J.H.E, E.K.A,
594 K.J.A, SJTRC Study Team. Writing, original draft: A.A.M. and M.V.P. Writing, review, and
595 editing: A.A.M, M.V.P, A.M.K, E.K.A, J.C.C, J.W, M.A.M, P.G.T. Visualization: A.A.M.
596 Supervision: P.G.T. Funding Acquisition: P.G.T.

597

598 **Competing interests**

599 P.G.T has consulted or received honorarium and travel support from Illumina and 10X. P.G.T.
600 serves on the Scientific Advisory Board of Immunoscope and Cytoagents.

601

602 **Supplementary information**

603 **Supplementary Table 1.** SARS-CoV-2 derived CD8⁺ epitopes used for MHC-multimer
604 generation.

605 **Supplementary Table 2.** Study participants metadata.


606 **Supplementary Table 3.** Mutations in studied epitopes from SARS-CoV-2 variants.

607 **Supplementary Table 4.** Differentially expressed genes for GEX clusters of epitope-specific
608 CD8⁺ T cells.

609 **Supplementary Table 5.** Epitope-specific CD8⁺ T cells GEX clusters, TCR and epitope
610 specificity.

611 **Supplementary Table 6.** Unique epitope-specific CD8⁺ $\alpha\beta$ TCR clonotypes.

612



613

614 **Fig 1. Measuring CD8+ T cell epitope-specific responses in SARS-CoV-2 naive and recovered**

615 **individuals after mRNA vaccination. a. Study design.** Left: Peripheral blood samples SARS-CoV-2

616 naive donors (n=9) and SARS-CoV-2 recovered donors (n=10) were collected after 2 doses of

617 Pfizer/BioNtech vaccine. For SARS-CoV-2 recovered donors, we collected another sample at a previous

618 timepoint before (purple, “post-infection”) or after vaccination (pink, “post-vax”). Time of blood sampling

619 for each donor is shown relative to the first dose of vaccine. Right: Selected spike and non-spike SARS-

620 CoV-2 T cell epitopes were loaded on recombinant biotinylated MHC-monomers. Resulting peptide-MHC

621 complexes were polymerized using fluorescently-labeled and DNA-barcoded dextran backbones. Next, we

622 stained PBMC samples with pools of MHC-multimers, isolated bound cells using FACS, and performed

623 scRNAseq, scTCRseq, and CITEseq using the 10X Genomics platform. **b. Anti-RBD IgG antibody levels**

624 **in SARS-CoV-2 recovered individuals increase after immunization with Pfizer-BioNTech BNT162b2**

625 **($p=0.016$, Wilcoxon signed-rank test).** Inset: after two doses of vaccine anti-RBD IgG levels are the same

626 for SARS-CoV-2 naive donors (green) and SARS-CoV-2 recovered donors (blue) ($p=0.18$, Wilcoxon rank-

627 sum test) and both are larger than post-infection levels in SARS-CoV-2 recovered donors (purple).

628 **c. List of SARS-CoV-2 epitopes used in this study.** Table shows peptide sequences, source proteins, and

629 summary statistics for resulting epitope-specific responses (number of HLA-matched samples with a

630 response and number of epitope-specific cells recovered from scRNAseq).


631 **d. Total frequency of MHC-dextramer-positive cells is similar in SARS-CoV-2 recovered individuals**

632 **post-infection (purple) and post-vaccination (blue), and in SARS-CoV-2 naive donors post-**

633 **vaccination (green).** Percentage of MHC-multimer-positive cells from all CD8+ T cells measured by flow


634 cytometry is shown on a log-scale.

635




636

637 **Figure 2. Magnitude, dynamics, and cross-reactivity of CD8+ epitope-specific responses to SARS-**
 638 **CoV-2 infection and vaccination. a. Antigen specificity of each T cell could be inferred from**
 639 **dextramer-barcode UMI counts.** Representative distribution of the number of UMIs in cells called
 640 dextramer-positive (pink) and dextramer-negative (yellow). **b. T cells within a clone have consistent**
 641 **specificity assignments, except T cells that cross-react with common cold coronavirus epitopes**
 642 **(B15_NQK_A/B15_NQK_Q pair).** Each bar shows a fraction of cells of a given clonotype attributed to
 643 different dextrans. The 15 most abundant clones (more than 12 cells) are shown. **c. The same cells bind**
 644 **both SARS-CoV-2 and CCCoV variants of the HLA-B*15:01-restricted spike-derived**
 645 **(NQKLIANA|QF) epitope.** Number of UMIs for B15_NQK_Q (SARS-CoV-2) and B15_NQK_A (OC43
 646 and HKU1) dextrans are correlated (Spearman $\rho=0.65$, $p<0.001$). **d. Cross-reactivity between HLA-**
 647 **B*15:01-NQK epitope variants confirmed *in vitro*.** Jurkat cell line expressing $\alpha\beta$ TCR identified from
 648 scTCRseq data binds pMHC multimers loaded with both SARS-CoV-2 and CCCoV variants of epitope. **e.**
 649 **A01_TTD, A01_LTD, A02_YLQ, B15_NQK epitopes elicit strongest T cell responses.** Each point is
 650 an estimated frequency of epitope-specific T cells in a sample. Estimated frequency was calculated as a
 651 fraction of dextramer-specific T cells in scRNAseq results multiplied by bulk frequency of dextramer-
 652 stained CD8+ cells of all CD8+ cells measured by flow cytometry. **f. Estimated frequency of spike-**
 653 **specific T cells are comparable between experimental groups (right).** A02_YLQ tends to elicit a stronger
 654 response in the context of vaccination (left). **g. Boosting of spike-specific epitope fraction after**
 655 **immunization (donor R6).** Each colored ribbon represents an estimated frequency of spike- (purple) or
 656 non-spike- (blue) specific T cell clones. **h. SARS-CoV-2 recovered individuals have a higher proportion**
 657 **of spike-specific T cells after vaccination than before vaccination.** The fraction of spike-specific T cells
 658 out of all epitope-specific T cells is plotted for paired post-infection and post-vaccination timepoints of
 659 COVID-19 recovered donors ($p=0.047$, Wilcoxon signed-rank test).




660
 661 **Figure 3. Phenotypic diversity of epitope-specific CD8 T cells after natural SARS-CoV-2 infection**
 662 **and vaccination. a. UMAP (Uniform manifold approximation and projection) of all SARS-CoV-2**
 663 **epitope-specific CD8 T cells based on gene expression (GEX). Color shows results of graph-based**
 664 **unsupervised clustering performed with the Seurat package. b. Density plot of CCR7 and CD45RA**
 665 **surface expression (measured by CITE-seq) in GEX clusters. c. Bubble plot of representative**
 666 **differentially expressed genes for each cluster. Size of the circle shows percentage of cells in a cluster**
 667 **expressing a certain gene, color scale shows gene expression level. d. Distribution of spike-specific (top**
 668 **subpanel) and non-spike-specific (bottom subpanel) T cells in gene expression clusters between study**
 669 **groups. Colors show corresponding clusters from a, b. e. Proportion of spike-specific T cells is**
 670 **significantly increased in EMRA cluster (cluster 1, green on d) after vaccination of SARS-CoV-2**
 671 **recovered individuals, compared to the pre-vaccination timepoint ($p=0.007$, one-tailed Wilcoxon**
 672 **rank-sum test). f. Clone size distribution within GEX clusters. Fractions of cells from 10 most abundant**
 673 **clonotypes in each cluster are shown with colors, all other clonotypes are shown in grey. Clusters 4, 6, and**
 674 **in particular 2 have the most expanded clones. g. Number of cells in cluster 2 (Exhausted) and cluster 6**
 675 **(Cycling) in samples are strongly correlated (Spearman $\rho=0.8$, $p<0.001$). Shaded area shows 95%**
 676 **confidence interval for linear fit. h. UMAP of spike-specific (bottom subpanel) and non-spike-specific**
 677 **(top subpanel) T cells sampled at two different timepoints from the same individuals based on GEX.**
 678 **Cluster 2 of exhausted T cells and cluster 6 of cycling T cells disappear at the later timepoint irrespective**
 679 **of T cell specificity (spike or non-spike). i. Distribution of cells from the largest observed clone between**
 680 **GEX clusters 7 days after the second dose (transparent dots) and 54 days after the second dose**
 681 **(opaque dots). Although the vast majority of cells from exhausted cluster 2 (purple) disappear, the clone**
 682 **persists in memory subpopulations. j. Vaccination of COVID-19 recovered does not affect spike-specific**
 683 **T cell repertoire diversity. Normalized Shannon entropy of TCR β is plotted for samples with more than**
 684 **3 unique TCR β clonotypes.**
 685




686
 687
 688
 689
 690
 691
 692
 693
 694
 695
 696
 697
 698
 699
 700


Figure 4. Both SARS-CoV-2 infection and vaccination activate diverse polyclonal repertoire of epitope-specific T cells with distinctive sequence motifs. a. SARS-CoV-2 epitope-specific $\alpha\beta$ TCR amino acid clonotypes feature clusters of highly similar sequences with the same epitope specificity. Each node on a similarity network is a unique paired $\alpha\beta$ TCR amino acid sequence, and an edge connects $\alpha\beta$ TCRs with TCRdist less than 120. Each color represents a certain epitope specificity. Clonotypes without neighbors are not shown. b. TCR amino acid sequence motifs of α and β chains (TCRdist logos) for the largest clusters of highly similar TCRs for each epitope (circled with dashed line on A). c. TCRs with the same sequence motifs are found both after natural infection, and post-vaccination of both naive and recovered subjects in a matching HLA-background. Occurrence of TCR motifs on the left is shown for all HLA matching and non-matching samples (rectangles on the plot). Grey rectangles represent samples lacking the TCR motif. The color of the rectangle that has a TCR motif corresponds to the sample group (purple for post-infection, pink, and blue for post-vaccination of recovered individuals, green for post-vaccination of naive individuals).




701
702 **Fig. S1. Subject selection for the study. a.** Time after second vaccination does not differ between
703 recovered and immunologically naive groups. **b.** HLA-type distribution is similar across study groups.



704
705 **Fig. S2. Antibody levels across study groups.** IgG levels to the receptor-binding domain (RBD) of the
706 spike (left) and whole spike (middle) of SARS-CoV are boosted in recovered donors after vaccination (IgG
707 RBD: $p=0.016$; IgG spike: $p=0.016$, Wilcoxon signed-rank test). Recovered donors after immunization
708 have similar RBD IgG antibody levels ($p=1$, Wilcoxon rank-sum test), and even higher spike IgG ($p=0.026$,
709 Wilcoxon rank-sum test) in comparison to SARS-CoV-2-naive vaccinated group. SARS-CoV-2 naive
710 individuals are negative for N-specific IgG. Purple line on the plots indicates the positivity threshold.




711
712 **Fig. S3. Gating strategy for sorting of single live CD3+CD8+dextramer+ cells.**




713

714 **Fig S4. Dextramer assignment with feature barcodes.** Each subplot shows distribution of $\text{Log}_{10}(\# \text{ UMIs})$
 715 for dextramers with certain feature barcodes in dextramer-negative (yellow) and dextramer-positive (pink)
 716 cells.




717


718 **Fig. S5. Peptide stimulation confirms cross-reactivity of B15_NQK $\alpha\beta$ TCR.** From left to right:
 719 unstimulated (negative control), NQKLIANQF (SARS-CoV-2) peptide stimulation, NQKLIANAF (OC43
 720 and HKU1) peptide stimulation, PMA/Ionomycin (positive control). Top row: IFN γ production by
 721 TCR-expressing Jurkats measured by intracellular cytokine staining. Middle row: CD69+ surface
 722 expression. Bottom row: NFAT-GFP reporter expression.



723
 724 **Fig S6. Antibody titers for CCCoV spike protein (HKU1 left panel, OC43 middle panel) and number**
 725 **of B15-NQF/NAF cross-reactive cells in HLA*B15:01+ donors (right panel, log-scale). Donor N1 has**
 726 **low levels of IgG anti-CCCoV antibodies and T cells cross-reactive with CCCoV derived HLA*B15:01-**
 727 **restricted epitope.**




728
 729 **Fig. S7. Clonal dynamics of spike and non-spike specific T cell response for each donor between two**
 730 **timepoints.** Each colored ribbon represents an estimated frequency of spike- (purple) or non-spike- (blue)
 731 **specific T cell clones. a.** Recovered donors (R1-R6), that have timepoint 1 sampled after the infection and
 732 **timepoint 2 sampled after second dose of the vaccine. b.** Recovered donors (R7, R8, R10), that have
 733 **timepoint 1 sampled after the first dose of the vaccine and timepoint 2 sampled after the second dose of the**
 734 **vaccine. c.** Recovered donor (R9), that have timepoint 1 sampled 7 days after the second dose of the vaccine
 735 **and timepoint 2 sampled 54 days after second dose of the vaccine.**



736


737 **Fig. S8. GEX cluster distribution for each sample.** Each coloured bar represents a fraction of cells in a
738 given GEX cluster. See Fig. 3 a, b for UMAP and cluster identities (the colour code for clusters is consistent
739 between figures).



740

741 **Fig. S9. UMAP visualization of cells clustered by similarity of GEX.** Each subpanel shows cells from
742 donors sampled at a given timepoint.


743



744

745 **Fig. S10. “Exhausted” cluster 2 (circled) is enriched with cells from expanded clones.** The color of
746 each dot shows the size of the T cell clone (Log_{10} of number of cells) for each cell.

747




748

749

750

751

Fig. S11. VJ-usage for immunodominant epitopes. Height of each rectangle corresponds to the fraction of unique epitope-specific T cell clones expressing a given V- or J-segment in the TCR α (a) and TCR β (b) chain. Ribbons show the frequency of VJ combinations.



752

753 **Fig. S12. Va-Vβ pairings for immunodominant epitopes.** Height of each rectangle corresponds to the
754 fraction of unique epitope-specific T cell clones expressing a given TRAV or TRBV-segment. Ribbons
755 show frequencies of TRAV-TRBV combinations.

756

757 **References**

- 758 Amanat, Fatima, Daniel Stadlbauer, Shirin Strohmeier, Thi H. O. Nguyen, Veronika
759 Chromikova, Meagan McMahon, Kaijun Jiang, et al. 2020. “A Serological Assay to
760 Detect SARS-CoV-2 Seroconversion in Humans.” *Nature Medicine* 26 (7): 1033–36.
761 <https://doi.org/10.1038/s41591-020-0913-5>.
- 762 Camara, Carmen, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados, Estela Paz-Artal, Marjorie
763 Pion, Rafael Correa-Rocha, Alberto Ortiz, et al. 2021. “Differential Effects of the Second
764 SARS-CoV-2 mRNA Vaccine Dose on T Cell Immunity in Naïve and COVID-19
765 Recovered Individuals.” Preprint. *Immunology*.
766 <https://doi.org/10.1101/2021.03.22.436441>.
- 767 Cornberg, Markus, Alex T. Chen, Lee A. Wilkinson, Michael A. Brehm, Sung-Kwon Kim,
768 Claudia Calcagno, Dario Gherzi, et al. 2006. “Narrowed TCR Repertoire and Viral
769 Escape as a Consequence of Heterologous Immunity.” *The Journal of Clinical*
770 *Investigation* 116 (5): 1443–56. <https://doi.org/10.1172/JCI27804>.
- 771 Csardi, Gabor, and Tamas Nepusz. 2006. “The Igraph Software Package for Complex Network
772 Research.” *InterJournal Complex Systems*: 1695.
- 773 Cukalac, Tania, Jesseka Chadderton, Andreas Handel, Peter C. Doherty, Stephen J. Turner, Paul
774 G. Thomas, and Nicole L. La Gruta. 2014. “Reproducible Selection of High Avidity
775 CD8+ T-Cell Clones Following Secondary Acute Virus Infection.” *Proceedings of the*
776 *National Academy of Sciences of the United States of America* 111 (4): 1485–90.
777 <https://doi.org/10.1073/pnas.1323736111>.
- 778 Cukalac, Tania, Jessica M. Moffat, Vanessa Venturi, Miles P. Davenport, Peter C. Doherty,
779 Stephen J. Turner, and John Stambas. 2009. “Narrowed TCR Diversity for Immunised
780 Mice Challenged with Recombinant Influenza A-HIV Env(311-320) Virus.” *Vaccine* 27
781 (48): 6755–61. <https://doi.org/10.1016/j.vaccine.2009.08.079>.
- 782 Dash, Pradyot, Andrew J. Fiore-Gartland, Tomer Hertz, George C. Wang, Shalini Sharma, Aisha
783 Souquette, Jeremy Chase Crawford, et al. 2017. “Quantifiable Predictive Features Define
784 Epitope-Specific T Cell Receptor Repertoires.” *Nature* 547 (7661): 89–93.
785 <https://doi.org/10.1038/nature22383>.
- 786 Diao, Bo, Chenhui Wang, Yingjun Tan, Xiewan Chen, Ying Liu, Lifan Ning, Li Chen, et al.
787 2020. “Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus

- 788 Disease 2019 (COVID-19).” *Frontiers in Immunology* 11 (May): 827.
789 <https://doi.org/10.3389/fimmu.2020.00827>.
- 790 Ebinger, Joseph E., Justyna Fert-Bober, Ignat Printsev, Min Wu, Nancy Sun, John C. Prostko,
791 Edwin C. Frias, et al. 2021. “Antibody Responses to the BNT162b2 mRNA Vaccine in
792 Individuals Previously Infected with SARS-CoV-2.” *Nature Medicine* 27 (6): 981–84.
793 <https://doi.org/10.1038/s41591-021-01325-6>.
- 794 Ferretti, Andrew P., Tomasz Kula, Yifan Wang, Dalena M.V. Nguyen, Adam Weinheimer,
795 Garrett S. Dunlap, Qikai Xu, et al. 2020. “Unbiased Screens Show CD8⁺ T Cells of
796 COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 That Largely Reside
797 Outside the Spike Protein.” *Immunity* 53 (5): 1095-1107.e3.
798 <https://doi.org/10.1016/j.immuni.2020.10.006>.
- 799 Francis, Joshua M., Del Leistriz-Edwards, Augustine Dunn, Christina Tarr, Jesse Lehman,
800 Conor Dempsey, Andrew Hamel, et al. 2021. “Allelic Variation in Class I HLA
801 Determines Pre-Existing Memory Responses to SARS-CoV-2 That Shape the CD8⁺ T
802 Cell Repertoire upon Viral Exposure.” Preprint. *Immunology*.
803 <https://doi.org/10.1101/2021.04.29.441258>.
- 804 Gangaev, Anastasia, Steven L. C. Ketelaars, Olga I. Isaeva, Sanne Patiwaël, Anna Dopler, Kelly
805 Hoefakker, Sara De Biasi, et al. 2021. “Identification and Characterization of a SARS-
806 CoV-2 Specific CD8⁺ T Cell Response with Immunodominant Features.” *Nature*
807 *Communications* 12 (1): 2593. <https://doi.org/10.1038/s41467-021-22811-y>.
- 808 Glanville, Jacob, Huang Huang, Allison Nau, Olivia Hatton, Lisa E. Wagar, Florian Rubelt,
809 Xuhuai Ji, et al. 2017. “Identifying Specificity Groups in the T Cell Receptor
810 Repertoire.” *Nature* 547 (7661): 94–98. <https://doi.org/10.1038/nature22976>.
- 811 Goel, Rishi R., Sokratis A. Apostolidis, Mark M. Painter, Divij Mathew, Ajinkya Pattekar, Oliva
812 Kuthuru, Sigrid Gouma, et al. 2021. “Distinct Antibody and Memory B Cell Responses
813 in SARS-CoV-2 Naïve and Recovered Individuals Following mRNA Vaccination.”
814 *Science Immunology* 6 (58): eabi6950. <https://doi.org/10.1126/sciimmunol.abi6950>.
- 815 Habel, Jennifer R., Thi H. O. Nguyen, Carolien E. van de Sandt, Jennifer A. Juno, Priyanka
816 Chaurasia, Kathleen Wragg, Marios Koutsakos, et al. 2020. “Suboptimal SARS-CoV-
817 2-specific CD8⁺ T Cell Response Associated with the Prominent HLA-A*02:01
818 Phenotype.” *Proceedings of the National Academy of Sciences* 117 (39): 24384–91.

- 819 <https://doi.org/10.1073/pnas.2015486117>.
- 820 Harris, Paul A., Robert Taylor, Brenda L. Minor, Veida Elliott, Michelle Fernandez, Lindsay
821 O’Neal, Laura McLeod, et al. 2019. “The REDCap Consortium: Building an
822 International Community of Software Platform Partners.” *Journal of Biomedical*
823 *Informatics* 95 (July): 103208. <https://doi.org/10.1016/j.jbi.2019.103208>.
- 824 Harris, Paul A., Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, and Jose
825 G. Conde. 2009. “Research Electronic Data Capture (REDCap)—A Metadata-Driven
826 Methodology and Workflow Process for Providing Translational Research Informatics
827 Support.” *Journal of Biomedical Informatics* 42 (2): 377–81.
828 <https://doi.org/10.1016/j.jbi.2008.08.010>.
- 829 Jacomy, Mathieu, Tommaso Venturini, Sebastien Heymann, and Mathieu Bastian. 2014.
830 “ForceAtlas2, a Continuous Graph Layout Algorithm for Handy Network Visualization
831 Designed for the Gephi Software.” Edited by Mark R. Muldoon. *PLoS ONE* 9 (6):
832 e98679. <https://doi.org/10.1371/journal.pone.0098679>.
- 833 Kared, Hassen, Andrew D. Redd, Evan M. Bloch, Tania S. Bonny, Hermi Sumatoh, Faris Kairi,
834 Daniel Carbajo, et al. 2021. “SARS-CoV-2–Specific CD8+ T Cell Responses in
835 Convalescent COVID-19 Individuals.” *Journal of Clinical Investigation* 131 (5):
836 e145476. <https://doi.org/10.1172/JCI145476>.
- 837 Krammer, Florian, Komal Srivastava, Hala Alshammery, Angela A. Amoako, Mahmoud H.
838 Awawda, Katherine F. Beach, Maria C. Bermúdez-González, et al. 2021. “Antibody
839 Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA
840 Vaccine.” *New England Journal of Medicine* 384 (14): 1372–74.
841 <https://doi.org/10.1056/NEJMc2101667>.
- 842 Kusnadi, Anthony, Ciro Ramírez-Suástegui, Vicente Fajardo, Serena J Chee, Benjamin J
843 Meckiff, Hayley Simon, Emanuela Pelosi, et al. 2021. “Severely Ill COVID-19 Patients
844 Display Impaired Exhaustion Features in SARS-CoV-2-Reactive CD8 + T Cells.” *Science*
845 *Immunology* 6 (55): eabe4782. <https://doi.org/10.1126/sciimmunol.abe4782>.
- 846 Malherbe, Laurent, Linda Mark, Nicolas Fazilleau, Louise J. McHeyzer-Williams, and Michael
847 G. McHeyzer-Williams. 2008. “Vaccine Adjuvants Alter TCR-Based Selection
848 Thresholds.” *Immunity* 28 (5): 698–709. <https://doi.org/10.1016/j.immuni.2008.03.014>.
- 849 Mazzoni, Alessio, Nicoletta Di Lauria, Laura Maggi, Lorenzo Salvati, Anna Vanni, Manuela

- 850 Capone, Giulia Lamacchia, et al. 2021. “First-Dose mRNA Vaccination Is Sufficient to
851 Reactivate Immunological Memory to SARS-CoV-2 in Subjects Who Have Recovered
852 from COVID-19.” *Journal of Clinical Investigation* 131 (12): e149150.
853 <https://doi.org/10.1172/JCI149150>.
- 854 Minervina, Anastasia A, Ekaterina A Komech, Aleksei Titov, Meriem Bensouda Koraichi, Elisa
855 Rosati, Ilgar Z Mamedov, Andre Franke, et al. 2021. “Longitudinal High-Throughput
856 TCR Repertoire Profiling Reveals the Dynamics of T-Cell Memory Formation after Mild
857 COVID-19 Infection.” *ELife* 10 (January): e63502. <https://doi.org/10.7554/eLife.63502>.
- 858 Nelde, Annika, Tatjana Bilich, Jonas S. Heitmann, Yacine Maringer, Helmut R. Salih, Malte
859 Roerden, Maren Lübke, et al. 2021. “SARS-CoV-2-Derived Peptides Define
860 Heterologous and COVID-19-Induced T Cell Recognition.” *Nature Immunology* 22 (1):
861 74–85. <https://doi.org/10.1038/s41590-020-00808-x>.
- 862 Nguyen, Thi H.O., Louise C. Rowntree, Jan Petersen, Brendon Y. Chua, Luca Hensen, Lukasz
863 Kedzierski, Carolien E. van de Sandt, et al. 2021. “CD8+ T Cells Specific for an
864 Immunodominant SARS-CoV-2 Nucleocapsid Epitope Display High Naive Precursor
865 Frequency and TCR Promiscuity.” *Immunity* 54 (5): 1066-1082.e5.
866 <https://doi.org/10.1016/j.immuni.2021.04.009>.
- 867 Nielsen, Stine SF, Line K Vibholm, Ida Monrad, Rikke Olesen, Giacomo S Frattari, Marie H
868 Pahus, Jesper F Højten, et al. 2021. “SARS-CoV-2 Elicits Robust Adaptive Immune
869 Responses Regardless of Disease Severity.” *EBioMedicine* 68 (June): 103410.
870 <https://doi.org/10.1016/j.ebiom.2021.103410>.
- 871 Oberle, Susanne G., Layane Hanna-El-Daher, Vijaykumar Chennupati, Sarah Enouz, Stefanie
872 Scherer, Martin Prlic, and Dietmar Zehn. 2016. “A Minimum Epitope Overlap between
873 Infections Strongly Narrows the Emerging T Cell Repertoire.” *Cell Reports* 17 (3): 627–
874 35. <https://doi.org/10.1016/j.celrep.2016.09.072>.
- 875 Painter, Mark M., Divij Mathew, Rishi R. Goel, Sokratis A. Apostolidis, Ajinkya Pattekar, Oliva
876 Kuthuru, Amy E. Baxter, et al. 2021. “Rapid Induction of Antigen-Specific CD4⁺ T
877 Cells Guides Coordinated Humoral and Cellular Immune Responses to SARS-CoV-2
878 mRNA Vaccination.” Preprint. *Immunology*. <https://doi.org/10.1101/2021.04.21.440862>.
- 879 Peng, Yanchun, Alexander J. Mentzer, Guihai Liu, Xuan Yao, Zixi Yin, Danning Dong,
880 Wanwisa Dejnirattisai, et al. 2020. “Broad and Strong Memory CD4⁺ and CD8⁺ T Cells

- 881 Induced by SARS-CoV-2 in UK Convalescent Individuals Following COVID-19.”
882 *Nature Immunology* 21 (11): 1336–45. <https://doi.org/10.1038/s41590-020-0782-6>.
- 883 Petrie, Joshua G., and Arnold S. Monto. 2017. “Untangling the Effects of Prior Vaccination on
884 Subsequent Influenza Vaccine Effectiveness.” *The Journal of Infectious Diseases* 215
885 (6): 841–43. <https://doi.org/10.1093/infdis/jix056>.
- 886 Reynisson, Birkir, Bruno Alvarez, Sinu Paul, Bjoern Peters, and Morten Nielsen. 2020.
887 “NetMHCpan-4.1 and NetMHCIIpan-4.0: Improved Predictions of MHC Antigen
888 Presentation by Concurrent Motif Deconvolution and Integration of MS MHC Eluted
889 Ligand Data.” *Nucleic Acids Research* 48 (W1): W449–54.
890 <https://doi.org/10.1093/nar/gkaa379>.
- 891 Rha, Min-Seok, Hye Won Jeong, Jae-Hoon Ko, Seong Jin Choi, In-Ho Seo, Jeong Seok Lee,
892 Moa Sa, et al. 2021. “PD-1-Expressing SARS-CoV-2-Specific CD8⁺ T Cells Are Not
893 Exhausted, but Functional in Patients with COVID-19.” *Immunity* 54 (1): 44-52.e3.
894 <https://doi.org/10.1016/j.immuni.2020.12.002>.
- 895 Robinson, James, Dominic J Barker, Xenia Georgiou, Michael A Cooper, Paul Flicek, and
896 Steven G E Marsh. 2019. “IPD-IMGT/HLA Database.” *Nucleic Acids Research*, October,
897 gkz950. <https://doi.org/10.1093/nar/gkz950>.
- 898 Sahin, Ugur, Alexander Muik, Evelyn Derhovanessian, Isabel Vogler, Lena M. Kranz, Mathias
899 Vormehr, Alina Baum, et al. 2020. “COVID-19 Vaccine BNT162b1 Elicits Human
900 Antibody and TH1 T Cell Responses.” *Nature* 586 (7830): 594–99.
901 <https://doi.org/10.1038/s41586-020-2814-7>.
- 902 Sahin, Ugur, Alexander Muik, Isabel Vogler, Evelyn Derhovanessian, Lena M. Kranz, Mathias
903 Vormehr, Jasmin Quandt, et al. 2021. “BNT162b2 Vaccine Induces Neutralizing
904 Antibodies and Poly-Specific T Cells in Humans.” *Nature*, May.
905 <https://doi.org/10.1038/s41586-021-03653-6>.
- 906 Saini, Sunil Kumar, Ditte Stampe Hersby, Tripti Tamhane, Helle Rus Povlsen, Susana Patricia
907 Amaya Hernandez, Morten Nielsen, Anne Orved Gang, and Sine Reker Hadrup. 2021.
908 “SARS-CoV-2 Genome-Wide T Cell Epitope Mapping Reveals Immunodominance and
909 Substantial CD8⁺ T Cell Activation in COVID-19 Patients.” *Science Immunology* 6 (58):
910 eabf7550. <https://doi.org/10.1126/sciimmunol.abf7550>.
- 911 Schattgen, Stefan A., Kate Guion, Jeremy Chase Crawford, Aisha Souquette, Alvaro Martinez

- 912 Barrio, Michael J.T. Stubbington, Paul G. Thomas, and Philip Bradley. 2020. “Linking T
913 Cell Receptor Sequence to Transcriptional Profiles with Clonotype Neighbor Graph
914 Analysis (CoNGA).” Preprint. *Immunology*. <https://doi.org/10.1101/2020.06.04.134536>.
- 915 Schreibing, Felix, Monica Hannani, Fabio Ticconi, Eleanor Fewings, James S Nagai, Matthias
916 Begemann, Christoph Kuppe, et al. 2021. “Dissecting CD8+ T Cell Pathology of Severe
917 SARS-CoV-2 Infection by Single-Cell Epitope Mapping.” Preprint. *Immunology*.
918 <https://doi.org/10.1101/2021.03.03.432690>.
- 919 Schulien, Isabel, Janine Kemming, Valerie Oberhardt, Katharina Wild, Lea M. Seidel, Saskia
920 Killmer, Sagar, et al. 2021. “Characterization of Pre-Existing and Induced SARS-CoV-2-
921 Specific CD8+ T Cells.” *Nature Medicine* 27 (1): 78–85. [https://doi.org/10.1038/s41591-
922 020-01143-2](https://doi.org/10.1038/s41591-020-01143-2).
- 923 Sekine, Takuya, André Perez-Potti, Olga Rivera-Ballesteros, Kristoffer Strålin, Jean-Baptiste
924 Gorin, Annika Olsson, Sian Llewellyn-Lacey, et al. 2020. “Robust T Cell Immunity in
925 Convalescent Individuals with Asymptomatic or Mild COVID-19.” *Cell* 183 (1): 158-
926 168.e14. <https://doi.org/10.1016/j.cell.2020.08.017>.
- 927 Shomuradova, Alina S., Murad S. Vagida, Savely A. Sheetikov, Ksenia V. Zornikova, Dmitry
928 Kiryukhin, Aleksei Titov, Iuliia O. Peshkova, et al. 2020. “SARS-CoV-2 Epitopes Are
929 Recognized by a Public and Diverse Repertoire of Human T Cell Receptors.” *Immunity*
930 53 (6): 1245-1257.e5. <https://doi.org/10.1016/j.immuni.2020.11.004>.
- 931 Snyder, Thomas M., Rachel M. Gittelman, Mark Klinger, Damon H. May, Edward J. Osborne,
932 Ruth Taniguchi, H. Jabran Zahid, et al. 2020. “Magnitude and Dynamics of the T-Cell
933 Response to SARS-CoV-2 Infection at Both Individual and Population Levels.” Preprint.
934 *Infectious Diseases (except HIV/AIDS)*. <https://doi.org/10.1101/2020.07.31.20165647>.
- 935 Stuart, Tim, Andrew Butler, Paul Hoffman, Christoph Hafemeister, Efthymia Papalexi, William
936 M. Mauck, Yuhan Hao, Marlon Stoeckius, Peter Smibert, and Rahul Satija. 2019.
937 “Comprehensive Integration of Single-Cell Data.” *Cell* 177 (7): 1888-1902.e21.
938 <https://doi.org/10.1016/j.cell.2019.05.031>.
- 939 Tarke, Alison, John Sidney, Conner K. Kidd, Jennifer M. Dan, Sydney I. Ramirez, Esther Dawen
940 Yu, Jose Mateus, et al. 2021. “Comprehensive Analysis of T Cell Immunodominance and
941 Immunoprevalence of SARS-CoV-2 Epitopes in COVID-19 Cases.” *Cell Reports
942 Medicine* 2 (2): 100204. <https://doi.org/10.1016/j.xcrm.2021.100204>.

943 Thevarajan, Irani, Thi H. O. Nguyen, Marios Koutsakos, Julian Druce, Leon Caly, Carolien E.
944 van de Sandt, Xiaoxiao Jia, et al. 2020. “Breadth of Concomitant Immune Responses
945 Prior to Patient Recovery: A Case Report of Non-Severe COVID-19.” *Nature Medicine*
946 26 (4): 453–55. <https://doi.org/10.1038/s41591-020-0819-2>.

947 Thimme, Robert, Valerie Oberhardt, Hendrik Luxenburger, Janine Kemming, Isabel Schulien,
948 Kevin Ciminski, Sebastian Giese, et al. 2021. “Rapid and Stable Mobilization of Fully
949 Functional Spike-Specific CD8+ T Cells Preceding a Mature Humoral Response after
950 SARS-CoV-2 mRNA Vaccination.” Preprint. In Review. <https://doi.org/10.21203/rs.3.rs-505193/v1>.

952 Wang, Zijun, Frauke Muecksch, Dennis Schaefer-Babajew, Shlomo Finklin, Charlotte Viant,
953 Christian Gaebler, Hans- Heinrich Hoffmann, et al. 2021. “Naturally Enhanced
954 Neutralizing Breadth against SARS-CoV-2 One Year after Infection.” *Nature*, June.
955 <https://doi.org/10.1038/s41586-021-03696-9>.

956 Zheng, Hong-Yi, Mi Zhang, Cui-Xian Yang, Nian Zhang, Xi-Cheng Wang, Xin-Ping Yang,
957 Xing-Qi Dong, and Yong-Tang Zheng. 2020. “Elevated Exhaustion Levels and Reduced
958 Functional Diversity of T Cells in Peripheral Blood May Predict Severe Progression in
959 COVID-19 Patients.” *Cellular & Molecular Immunology* 17 (5): 541–43.
960 <https://doi.org/10.1038/s41423-020-0401-3>.

961
962
963
964